Eli Lilly (LLY) reported a strong Q1, highlighting its leadership in the expanding GLP-1 drug market, primarily driven by its products Mounjaro and Zepbound. Despite this impressive performance, the stock has retraced from its earlier highs above $1,100 and is currently trading around $960. Analysts remain bullish, with a consensus price target of approximately $1,215, suggesting a potential upside of 26% for investors.
The recent decline in Eli Lilly’s stock price has made its valuation more attractive, especially in light of a nearly 60% revenue growth reported last quarter. While the price-to-earnings multiple is not the lowest, it reflects a more favorable investment opportunity for a high-growth company. With strong fundamentals and a robust growth trajectory, many analysts still foresee the stock surpassing the $1,000 mark soon.
For market professionals, Eli Lilly presents a compelling case as a potential buy, especially for those looking at long-term growth, given its solid earnings and improving valuation metrics.
Source: fool.com